DANTROLENE SODIUM IS a muscle relaxant that acts
|
|
- Marybeth Morrison
- 5 years ago
- Views:
Transcription
1 ORIGINAL ARTICLE Safety of Low-Dose Oral Dantrolene Sodium on Hepatic Function Jung Yoon Kim, MD, Sewoong Chun, MD, Moon Suk Bang, MD, PhD, Hyung-Ik Shin, MD, PhD, Shi-Uk Lee, MD, PhD ABSTRACT. Kim JY, Chun S, Bang MS, Shin H-I, Lee S-U. Safety of low-dose oral dantrolene sodium on hepatic function. Arch Phys Med Rehabil 2011;92: Objective: To investigate the incidence of hepatobiliary dysfunction after administration of low-dose dantrolene sodium. Design: A retrospective survey of medical records. Setting: One secondary and 2 tertiary hospitals. Participants: Patients (N 243; 144 men, 27 children; mean age SD, y) who were administered dantrolene at a daily dose of 12.5 to 400mg for more than 4 weeks. Interventions: Not applicable. Main Outcome Measures: Liver function test (LFT) results, including serum total bilirubin, aspartate transaminase, alanine transaminase, and alkaline phosphatase, were recorded before and at least 1 month after the initial dose of dantrolene. In cases of treatment cessation, the reason was investigated. Significantly elevated LFT levels were defined as to 2 times the upper limit of the normal range. Results: Treatment duration was days with a daily dose of mg. At the end of the investigation, 95 patients (39.1%) had been lost to follow-up, and 105 (43.2%) had stopped treatment. The reasons for cessation were improved spasticity (42.9%), no effect of the medication (27.6%), weakness (6.7%), and other medical problems (5.7%). Patients with weaknesses did not have elevated LFT values. A 32-yearold man with head injuries and multiple trauma developed hepatic dysfunction 82 days after the initial dose and 43 days after a dose increment to 400mg/d. Other patients did not experience significant LFT abnormalities. Conclusions: One case of hepatic dysfunction was recorded in 243 cases after at least 4 weeks of low-dose oral dantrolene administration. Low-dose dantrolene can be used safely with meticulous clinical and laboratory monitoring. Key Words: Dantrolene; Drug toxicity; Muscle spasticity; Rehabilitation by the American Congress of Rehabilitation Medicine From the Department of Rehabilitation Medicine, Seoul National University College of Medicine, Seoul (Kim, Chun, Bang, Shin, Lee); Department of Rehabilitation Medicine, Seoul National University Hospital, Seoul (Kim, Chun, Bang); Department of Rehabilitation Medicine, Seoul National University Bundang Hospital, Seoul (Shin); and Department of Rehabilitation Medicine, Seoul National University Boramae Hospital, Seoul (Lee), Korea. No commercial party having a direct financial interest in the results of the research supporting this article has or will confer a benefit on the authors or on any organization with which the authors are associated. Correspondence to Shi-Uk Lee, MD, PhD, Department of Rehabilitation Medicine, Seoul National University Boramae Medical Center, 39 Boramae-gil, Dong-jak gu, Seoul, Korea, paindoc@snu.ac.kr. Reprints are not available from the authors /11/ $36.00/0 doi: /j.apmr DANTROLENE SODIUM IS a muscle relaxant that acts directly on muscles by decreasing calcium release from the sarcoplasmic reticulum. 1 Dantrolene predominantly influences skeletal muscles instead of smooth muscles. As such, it successfully alleviates spasticity resulting from neuromuscular diseases including stroke, traumatic brain injury, spinal cord injury, cerebral palsy, and multiple sclerosis. 2-4 In contrast to other muscle relaxants acting on the central nervous system, dantrolene has fewer adverse reactions related to the central nervous system. 5 However, reported cases of fatal hepatic injuries induced by dantrolene have prevented its widespread use. Dantrolenerelated hepatic dysfunction varies from a slight elevation in liver enzyme levels to fatal hepatic injury. The incidence of hepatic dysfunction and fatal hepatic injury was reported to be 1.8% and.35%, respectively. 6 More recently, researchers from the United States reported 122 cases of hepatic dysfunction related to dantrolene until 1987, of which 27 were fatal. The dantrolene dosage in the fatal cases was 582mg/d, and the administration period was months. Most of the deceased patients were adults. 7 The suggested mechanisms of dantrolene-induced hepatic dysfunction include direct hepatotoxicity, a drug-induced idiosyncratic reaction, and an autoimmune-mediated reaction, 6-8 but the exact mechanism has not yet been established. Currently, dantrolene is used with much caution in adults, and the recommended daily dose is 12.5 to 400mg. 1 Despite the recommendation of low-dose dantrolene use, there have never been any safety reports on the use of low-dose dantrolene in adults or in children. In this study, we aimed to investigate the incidence of dantrolene-related hepatic dysfunction with low-dose (25 400mg daily) oral administration, and its safety in general. METHODS Participants Study subjects included patients who had been administered dantrolene sodium for 4 weeks or more, between January 2005 and February 2009, at the Department of Rehabilitation Medicine in 1 secondary and 2 tertiary hospitals. Institutional review board approvals were obtained before the survey. Data Collection Procedures Medical records of the subjects were reviewed to obtain the following information: age, sex, causal disease that ALP ALT AST HBsAg LFT List of Abbreviations alkaline phosphatase alanine transaminase aspartate transaminase hepatitis B surface antigen liver function test 1359
2 1360 SAFETY OF LOW-DOSE DANTROLENE SODIUM, Kim Fig 1. Flow chart illustrating subject breakdown at each step of the study. resulted in spasticity, daily dose and administration duration of dantrolene, preadministration and postadministration liver function test (LFT) values, and reasons for dantrolene discontinuation. The levels of serum total bilirubin, aspartate transaminase (AST), alanine transaminase (ALT), and alkaline phosphatase (ALP) were recorded. LFT results before the first dose of dantrolene, usually within 4 weeks, were accepted as preadministration LFTs. 9 Postadministration LFT values were accepted when those were obtained more than 4 weeks after the first dose during the administration of dantrolene. In cases of dantrolene discontinuation, the reasons were determined, and any adverse reactions related to dantrolene were recorded. Main Outcome Measures The number and ratio of patients who showed elevated serum total bilirubin, AST, ALT, and ALP levels were recorded. A significant elevation in serum LFT levels was defined as any increase that was more than twice the upper reference limit. 10 The ratio of the number of subjects with elevated LFT values to the total number of subjects was defined as the incidence of hepatic dysfunction. In cases of hepatic dysfunction after dantrolene administration, the causal relationship between medication and elevated LFT values was assessed by using a scoring system for assessing causality for hepatocellular/cholestatic types of reactions, 11,12 which is a scoring system that encompasses the temporal relationship, time course, risk factors, concomitant drug and nondrug causes, previous information on hepatotoxicity of the drug, and rechallenge. Any occurrence of acute liver failure, defined as hepatic dysfunction with coagulation abnormalities and encephalopathy, was investigated. 13 Hepatic dysfunction was classified into 4 categories 6 : (1) serum enzyme elevation only; (2) enzyme elevation with a serum bilirubin level of 2.5mg/dL or less; (3) jaundice or a serum bilirubin level greater than 2.5mg/dL; and (4) fatal hepatic dysfunction. Statistical Analysis Differences between preadministration and postadministration LFT values were investigated using the paired t test. All statistical analyses were conducted using SPSS for Windows version a A P value less than.05 was considered statistically significant. All values were presented as mean SD. Ranges were described as the lowest and the highest values from the observed data. RESULTS Participant Characteristics A total of 243 patients (144 men, 27 children) were prescribed dantrolene for 4 weeks or more during the study period. Their age was years (children, y; adults, y). Administration of Dantrolene Sodium The duration of administration was days (range, d), and the dosage was mg/d (range, mg/d). Ninety-five patients (39.1%) were lost to follow-up, 43 (17.7%) were still taking dantrolene at the end of survey, and 105 (43.2%) had stopped the medication (fig 1). Reasons for Discontinuing Table 1: Discontinuation No. of Subjects Children Adults Total Improved spasticity No effect of medication Unknown causes General weakness Other medical problems Botulinum toxin injection Elevated liver enzymes Total
3 SAFETY OF LOW-DOSE DANTROLENE SODIUM, Kim 1361 Characteristic Frequency (n) % Table 2: Age Distribution and Daily Dose of Dantrolene Subjects With Preadministration and Postadministration LFTs (n) % Age (y) Total Daily dose (mg/d) Total The reasons for discontinuation are listed in table 1. LFT Levels LFT values before and after dantrolene administration were available in 92 subjects (16 children, 76 adults), and their mean age SD was years ( y in children, y in adults). The age distribution of the subjects is listed in table 2. They had taken dantrolene for days (range, d) with a daily dose of mg (range, mg). The daily dose was 12.5 to 200mg in 87 subjects (94.6%) (see table 2). There were no significant differences between preadministration and postadministration LFT levels in children (P.864, P.151, P.912, and P.497 in total bilirubin, AST, ALT, and ALP levels, respectively, by paired t test) and in adults (P.583, P.569, P.912, and P.497 in total bilirubin, AST, ALT, and ALP levels, respectively, by paired t test) (table 3). Seven patients who developed weakness and stopped dantrolene did not have LFT abnormalities. In a 32-year-old man with head injuries and multiple traumas, elevated LFT values resulted in cessation of dantrolene. He was a hepatitis B surface antigen (HBsAg) carrier. His LFT values 20 days before the initial dose were as follows: total bilirubin, 0.5mg/dL; AST, 54IU/L; ALT, 123IU/L; and ALP, 167IU/L. Although AST, ALT, and ALP levels were above the reference limits, dantrolene was administrated to relieve spasticity. Silymarin and biphenyl dimethyl dicarboxylate were prescribed as hepatic protective agents, and LFTs were assessed every 3 to 7 days. He had taken dantrolene 75mg/d for 6 days, and 150mg/d for 33 days successively. The daily dose was then increased to 400mg (5.9mg/kg), and 4 days later, when he had been taking dantrolene for 47 days, his AST level was elevated to 121IU/L. However, it decreased to 57IU/L 3 days later without interrupting dosing. On the 82nd day after the initial dose and 43rd day after the dose increment, his ALP level rose to 245IU/L and AST level increased to 85IU/L, which were above the upper reference limits. Dantrolene administration was stopped at the 155th day. Because his serum bilirubin level was greater than 2.5mg/dL, this adverse reaction belongs to the third category of dantrolene-induced hepatic dysfunction. The patient s ALP and AST levels remained elevated until dantrolene administration was ceased, leading clinicians to suspect that his chronic hepatitis B had become active. After cessation of dantrolene, his serum total bilirubin and ALP levels began to decrease, but the increased AST and ALT levels persisted. He was lost to follow-up, but when readmitted 2 years later owing Table 3: Levels of Preadministration and Postadministration LFTs in Children and Adults Children Adults Preadministration Postadministration Preadministration Postadministration Total bilirubin (mg/dl) AST (IU/L) ALT (IU/L) ALP (IU/L) NOTE. Values are mean SD.
4 1362 SAFETY OF LOW-DOSE DANTROLENE SODIUM, Kim Table 4: Subjects Who Developed Generalized Weakness Patient No. Sex Age (y) Diagnosis Daily Dose (mg) Duration of Administration (d) 1 M 5 Cerebral palsy M 10 Cerebral palsy M 26 Cerebral palsy M 41 Cerebral palsy M 50 Stroke M 62 Stroke M 51 Spinal cord injury Abbreviation: M, male. to chronic osteomyelitis, his LFT levels were within the reference limits. All the other patients did not show any significant elevations in postadministration LFT levels compared with those preadministration. Seven male subjects complained of general weakness (2 were children with cerebral palsy, 5 were adults) (table 4). When this symptom was considered as an adverse effect of dantrolene, 8 subjects (7 men with general weakness, 1 man with liver enzyme elevation) had developed adverse reactions. They were taking 25 to 300mg of dantrolene for 45 to 1028 days (see table 4). However, reported general weakness is a subjective and vague complaint, and can also be a manifestation of fatigue. DISCUSSION This survey investigated adverse effects detected in subjects taking dantrolene within a low-dose recommended range. Among the 92 subjects with preadministration and postadministration LFT values, 1 had developed hepatic dysfunction (incidence, 1.09%). There were no reports of adverse reactions related to dantrolene in 151 subjects who did not have preadministration and postadministration LFTs. Between 28 and 2517 days (mean SD, d) of follow-up, no fatal hepatic injury had occurred in 243 patients. Regular LFT monitoring for a much longer follow-up period may be necessary in the subjects in this study, who had been taking dantrolene for days ( mo). This is because in a previous report, subjects who had taken 201 to 400mg/d of dantrolene accounted for as many as 23% of patients with fatal hepatic injuries, which occurred after months. 7 However, the incidence of fatal hepatic injury in subjects of this study might be very low thereafter, because the daily dose was 100mg or less in 95.9% of all 243 subjects, and in 91.3% of 92 subjects with preadministration and postadministration LFT levels. Dantrolene-induced hepatic dysfunction has been shown to have a dose-response relationship, 7 and there have been no reports of fatal hepatic injury induced by dantrolene at a daily dose of 200mg or less. A patient who had developed LFT abnormalities in this study tested positive for serum HBsAg and had liver enzyme levels that surpassed the upper reference limits. We could not apply the scoring system for assessing causality for hepatocellular/cholestatic types of reactions to this patient because of a lack of information after dantrolene cessation. Dantrolene is suspected of causing the aggravated hepatic dysfunction in this patient because his LFT values decreased after dantrolene was discontinued. We suggest that obtaining screening LFTs before administering dantrolene and avoiding dantrolene in patients with underlying liver disease may be helpful to minimize dantrolene-induced hepatic dysfunction. Moreover, monitoring LFT values more frequently than previously recommended 7,14,15 may be necessary to detect dantrolene-induced hepatic dysfunction. We suggest monthly screening tests, as the above case presented hepatic dysfunction 43 days after a dose increase. There had been no significant elevation in LFT levels until a dose increment, and other patients were administered less than 200mg of dantrolene, consistent with previous reports. 5,6 As such, a daily dose of less than 200mg may be safely used. Study Limitations A relatively small number of subjects compared with previous studies 6,7 makes it difficult to confirm that no fatal hepatic dysfunction occurs with a dantrolene dosage of 200mg/d or less. A larger cohort might be more informative. Asymptomatic hepatic dysfunction had no chance to be discovered in the 107 patients who did not have LFT results. A detection bias of symptomatic dysfunction may be possible. CONCLUSIONS Only 1 of 243 subjects had significant hepatic dysfunction after at least 4 weeks of low-dose oral dantrolene sodium administration. Low-dose dantrolene sodium could be used safely with clinical and laboratory monitoring. References 1. Ward A, Chaffman MO, Sorkin EM. Dantrolene. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity. Drugs 1986; 32: Chyatte SB, Basmajian JV. Dantrolene sodium: long-term effects in severe spasticity. Arch Phys Med Rehabil 1973;54: Denhoff E, Feldman S, Smith MG, Litchman H, Holden W. Treatment of spastic cerebral-palsied children with sodium dantrolene. Dev Med Child Neurol 1975;17: Dykes MH. Evaluation of a muscle relaxant: dantrolene sodium (Dantrium). JAMA 1975;231: Gracies JM, Nance P, Elovic E, McGuire J, Simpson DM. Traditional pharmacological treatments for spasticity. Part II: general and regional treatments. Muscle Nerve Suppl 1997;6:S Utili R, Boitnott JK, Zimmerman HJ. Dantrolene-associated hepatic injury. Incidence and character. Gastroenterology 1977;72: Chan CH. Dantrolene sodium and hepatic injury. Neurology 1990; 40: Durham JA, Gandolfi AJ, Bentley JB. Hepatotoxicological evaluation of dantrolene sodium. Drug Chem Toxicol 1984;7: Graham DJ, Drinkard CR, Shatin D, Tsong Y, Burgess MJ. Liver enzyme monitoring in patients treated with troglitazone. JAMA 2001;286:831-3.
5 SAFETY OF LOW-DOSE DANTROLENE SODIUM, Kim Bleibel W, Kim S, D Silva K, Lemmer ER. Drug-induced liver injury: review article. Dig Dis Sci 2007;52: Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 1993;46: Danan G, Benichou C. Causality assessment of adverse reactions to drugs I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993;46: Polson J, Lee WM. AASLD position paper: the management of acute liver failure. Hepatology 2005;41: Kita M, Goodkin DE. Drugs used to treat spasticity. Drugs 2000; 59: Wilkinson SP, Portmann B, Williams R. Hepatitis from dantrolene sodium. Gut 1979;20:33-6. Supplier a. SPSS Inc, 233 S Wacker Dr, 11th Fl, Chicago, IL
Drug Induced Liver Injury (DILI)
Drug Induced Liver Injury (DILI) Aisling Considine- Consultant Hepatology Pharmacist. King s College Hospital NHS Foundation Trust aislingconsidine@nhs.net Drug Induced Liver Injury /Disease Acute Liver
More informationEffect of Prophylactic Use of Silymarin on Anti-tuberculosis Drugs Induced Hepatotoxicity
ORIGINAL ARTICLE https://doi.org/.446/trd.217.8.3.26 ISSN: 1738-336(Print)/2-6184(Online) Tuberc Respir Dis 217;8:26-269 Effect of Prophylactic Use of Silymarin on Anti-tuberculosis Drugs Induced Hepatotoxicity
More informationGSK Medicine: Study No.: Title: Rationale: before initiation of treatment, every 4-6 weeks during treatment
GSK Medicine: Lapatinib Study No.: WWE115270/WEUKSTV4275 Title: Assessment of Physician Compliance to Recommend Liver Function Test (LFT) Monitoring for Lapatinib Patients Rationale: Lapatinib (Tykerb
More informationManagement of Acute HCV Infection
Management of Acute HCV Infection This section provides guidance on the diagnosis and medical management of acute HCV infection, which is defined as presenting within 6 months of the exposure. During this
More informationEvaluation of prognostic markers in severe drug-induced liver disease
PO Box 2345, Beijing 100023, China World J Gastroenterol 2007 January 28; 13(4): 628-632 World Journal of Gastroenterology ISSN 1007-9327 wjg@wjgnet.com 2007 The WJG Press. All rights reserved. RAPID COMMUNICATION
More informationCITY AND HACKNEY CCG ABNORMAL LIVER FUNCTION TESTS (LFTs) in ADULTS
CITY AND HACKNEY CCG ABNORMAL LIVER FUNCTION TESTS (LFTs) in ADULTS Interpreting abnormal liver function tests (LFTs) and trying to diagnose any underlying liver disease is a common scenario in Primary
More informationManagement of Patients with Past or Present Hepatic Abnormalities
S21 Management of Patients with Past or Present Hepatic Abnormalities Evidence Based Medicine Official recommendations Expert opinion Course of action before tocilizumab therapy in patients with a history
More information1. Based on A.S. s labs and presentation, what type of liver injury would you classify her as experiencing?
Drug Induced Liver Injury Cases Case #1 A.S., a16 year-old female, was found by her pediatrician to be slightly jaundiced during a routine school physical. She denied any history of liver disease, abdominal
More informationLong-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance
Long-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance Gi-Ae Kim, Han Chu Lee *, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim,
More informationNERVOUS SYSTEM NERVOUS SYSTEM. Somatic nervous system. Brain Spinal Cord Autonomic nervous system. Sympathetic nervous system
SYNAPTIC NERVOUS SYSTEM NERVOUS SYSTEM CENTRAL NERVOUS SYSTEM PERIPHERAL NERVOUS SYSTEM Brain Spinal Cord Autonomic nervous system Somatic nervous system Sympathetic nervous system Parasympathetic nervous
More informationMalignancies in Korean Patients with Inflammatory Myopathy
Yonsei Medical Journal Vol. 47, No. 4, pp. 519-523, 2006 Malignancies in Korean Patients with Inflammatory Myopathy Sang-Won Lee, Sang Youn Jung, Min-Chan Park, Yong-Beom Park, and Soo-Kon Lee Division
More informationLESSON ASSIGNMENT. LESSON OBJECTIVES 3-1. Given a group of definitions, select the definition of the term muscle relaxant.
LESSON ASSIGNMENT LESSON 3 Skeletal Muscle Relaxants. TEXT ASSIGNMENT Paragraphs 3-1 through 3-7. LESSON OBJECTIVES 3-1. Given a group of definitions, select the definition of the term muscle relaxant.
More informationDiagnostic evaluation of suspected Drug-Induced Liver Injury
Diagnostic evaluation of suspected Drug-Induced Liver Injury Ynto de Boer, MD Department of Gastroenterology and Hepatology Disclosure No disclosures Drug-induced liver injury? Outline What is DILI? What,
More informationNCCP Chemotherapy Regimen. PAZOPanib Therapy
INDICATIONS FOR USE: PAZOPanib Therapy Regimen Code INDICATION ICD10 First line treatment of advanced Renal Cell Carcinoma (RCC) in adults and for C64 00445a patients who have received prior cytokine therapy
More informationAbstract AIM: To analyze the clinical features of druginduced liver injury (DILI), and discuss the risk factors affecting its prognosis.
: http://www.baishideng.com/wcjd/ch/index.aspx : http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.11569/wcjd.v24.i8.1257 2016 3 18 ; 24(8): 1257-1263 ISSN 1009-3079 (print) ISSN 2219-2859 (online) 2016
More informationAnnex IV Scientific conclusions
Annex IV Scientific conclusions 56 Scientific conclusions On 7 June 2017, the European Commission (EC) was informed of a fatal case of fulminant liver failure in a patient treated with daclizumab in an
More informationThe effect of dantrolene sodium in relation to blood levels in spastic patients after prolonged administration
Journal of Neurology, Neurosurgery, and Psychiatry, 1981, 44, 334-339 The effect of dantrolene sodium in relation to blood levels in spastic patients after prolonged administration W J MEYLER,* H BAKKER,t
More informationOverview of Causality Assessment in Drug-Induced Liver Injury
REVIEW Overview of Causality Assessment in Drug-Induced Liver Injury Paul H. Hayashi, M.D., M.P.H. The diagnosis of drug-induced (or herbal/dietary supplement induced) liver injury (DILI) remains largely
More informationDrug Induced Liver Injury Associated with Daptomycin: A Case Report and Cohort
AAC Accepts, published online ahead of print on 12 May 2014 Antimicrob. Agents Chemother. doi:10.1128/aac.03157-14 Copyright 2014, American Society for Microbiology. All Rights Reserved. 1 2 Drug Induced
More informationDOSING AND ADMINISTRATION GUIDE
DOSING AND ADMINISTRATION GUIDE Indication TAVALISSE is a kinase inhibitor indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient
More informationABNORMAL LIVER FUNCTION TESTS. Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust
ABNORMAL LIVER FUNCTION TESTS Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust INTRODUCTION Liver function tests Cases Non invasive fibrosis measurement Questions UK MORTALITY RATE
More informationHow to use statins in patients with chronic liver disease
REVIEW CME CREDIT MARK W. RUSSO, MD Center for the Study of Hepatitis C, Division of Gastroenterology and Hepatology, Weill Cornell Medical College, New York, NY IRA M. JACOBSON, MD Center for the Study
More informationIntrathecal Baclofen for Spasticity. Dr. M. Mehra Dr. A. Kumar
Intrathecal Baclofen for Spasticity Dr. M. Mehra Dr. A. Kumar Goals of Spasticity: Management Decrease spasticity Improve functional ability and independence Decrease pain associated with spasticity Prevent
More informationEVALUATION OF ABNORMAL LIVER TESTS
EVALUATION OF ABNORMAL LIVER TESTS MIA MANABAT DO PGY6 MOA 119 TH ANNUAL SPRING SCIENTIFIC CONVENTION MAY 19, 2018 EVALUATION OF ABNORMAL LIVER TESTS Review of liver enzymes vs liver function tests Clinical
More informationAmmonia level at admission predicts in-hospital mortality for patients with alcoholic hepatitis
Gastroenterology Report, 5(3), 2017, 232 236 doi: 10.1093/gastro/gow010 Advance Access Publication Date: 1 May 2016 Original article ORIGINAL ARTICLE Ammonia level at admission predicts in-hospital mortality
More informationThe natural history of histologically proved drug induced liver disease
Gut 1999;44:731 735 731 The natural history of histologically proved drug induced liver disease Centre for Liver Research, The Medical School, Framlington Place, Newcastle-upon-Tyne NE2 4HH, UK P G Aithal
More informationACTEMRA Risk Mitigation Strategy Presenter Name, Degree
ACTEMRA Risk Mitigation Strategy Presenter Name, Degree Medical Science Liaison Genentech, Inc. 1 Indications and Dosage Rheumatoid Arthritis (RA) (1 of 2) Indication in RA ACTEMRA (tocilizumab) is indicated
More informationA PARTNERSHIP PLAN FOR IDIOPATHIC PULMONARY FIBROSIS
A PARTNERSHIP PLAN FOR IDIOPATHIC PULMONARY FIBROSIS A STRATEGY FOR DEVELOPING AN IPF MANAGEMENT PLAN BASED ON REALISTIC PATIENT GOALS Indication Esbriet (pirfenidone) is indicated for the treatment of
More informationDiagnosis of Acute HCV Infection
Hepatitis C Online PDF created December 20, 2017, 7:54 pm Diagnosis of Acute HCV Infection This is a PDF version of the following document: Module 1: Screening and Diagnosis of Hepatitis C Infection Lesson
More informationA Rational Evidence-based Approach to Abnormal Liver Tests
A Rational Evidence-based Approach to Abnormal Liver Tests Jane D. Ricaforte-Campos, MD FPCP, FPSG, FPSDE 2013 HSP Post-graduate Course Radisson Blu Hotel, Cebu City misnomer Liver Function Tests Does
More informationAbnormal Liver Chemistries. Lauren Myers, MMsc. PA-C Oregon Health and Science University
Abnormal Liver Chemistries Lauren Myers, MMsc. PA-C Oregon Health and Science University Disclosure 1. The speaker/planner Lauren Myers, MMSc, PA-C have no relevant financial relationships to disclose
More informationSAFETY CONSIDERATIONS WITH YONDELIS (trabectedin)
SAFETY CONSIDERATIONS WITH YONDELIS (trabectedin) Please see Important Safety Information on pages 14 and 15 and accompanying full Prescribing Information. YONDELIS (trabectedin) STUDY DESIGN INDICATION
More informationSkeletal Muscle Relaxants. Munir Gharaibeh, MD, PhD, MHPE Faculty of Medicine, The University of Jordan March, 2014
Skeletal Muscle Relaxants Munir Gharaibeh, MD, PhD, MHPE Faculty of Medicine, The University of Jordan March, 2014 The nicotinic Acetycholine receptor Present at the neuromuscular junction, peripheral
More informationNEUROMUSCULAR BLOCKING AGENTS
NEUROMUSCULAR BLOCKING AGENTS Edward JN Ishac, Ph.D. Associate Professor, Pharmacology and Toxicology Smith 742, 828-2127, Email: eishac@vcu.edu Learning Objectives: 1. Understand the physiology of the
More informationRisk Factors Affecting Adverse Effects of Cyclosporine A in a Real-World Psoriasis Treatment
pissn 1013-9087ㆍeISSN 2005-3894 Ann Dermatol Vol. 30, No. 2, 2018 https://doi.org/10.5021/ad.2018.30.2.143 ORIGINAL ARTICLE Risk Factors Affecting Adverse Effects of Cyclosporine A in a Real-World Psoriasis
More informationBosentan Accord Prescriber s Guide. This guide provides important safety information about Bosentan Accord regarding the risk
Bosentan Accord Prescriber s Guide This guide provides important safety information about Bosentan Accord regarding the risk of liver injury and birth defects. Information is provided concerning the monitoring
More informationPresentation and mortality of primary biliary cirrhosis in older patients
Age and Ageing 2000; 29: 305 309 Presentation and mortality of primary biliary cirrhosis in older patients JULIA L. NEWTON 1,DAVID E. JONES 2,JANE V. METCALF 2,JAY B. PARK 2,ALISTAIR D. BURT 2, MARGARET
More informationRecent Status of Drug-induced Liver Injury and Its Problems in Japan
Research and Reviews Recent Status of Drug-induced Liver Injury and Its Problems in Japan JMAJ 53(4): 243 247, 2010 Hajime TAKIKAWA* 1 Abstract Adverse drug reactions are becoming a social issue in recent
More informationValdoxan (agomelatine) in the treatment of Major Depressive Episodes in Adults. Prescriber Guide Information for Healthcare Professionals
Important information Do not discard! Valdoxan (agomelatine) in the treatment of Major Depressive Episodes in Adults Prescriber Guide Information for Healthcare Professionals Recommendations regarding:
More informationBOTULINUM TOXIN AND INTRATHECAL BACLOFEN. Spencer Cotterell DO Mercy Rehabilitation Hospital June 30, 2018
BOTULINUM TOXIN AND INTRATHECAL BACLOFEN Spencer Cotterell DO Mercy Rehabilitation Hospital June 30, 2018 INJECTABLES MEDICAL MANAGEMENT OF SPASTICITY Leonard, J In: Botulinum toxin: 2009 A protein and
More informationRESEARCH ARTICLE. Mohammad Reza SALEHIOMRAN MD 1, Seyyed Esmaeil HOSSEINI KORDKHEILY MD 2
RESEARCH ARTICLE THE EFFECT OF ANTICONVULSANT DRUGS (PHENOBARBITAL AND VALPROIC ACID) ON THE SERUM LEVEL OF CHOLESTEROL, TRIGLYCERIDE, LIPOPROTEIN AND LIVER ENZYMES IN CONVULSIVE CHILDREN Mohammad Reza
More informationIn 1993, the International Autoimmune Hepatitis Group
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2012;10:417 421 Validation and Modification of Simplified Diagnostic Criteria for Autoimmune Hepatitis in Children ELIZABETH MILETI,* PHILIP ROSENTHAL,*, and MARION
More informationComparing Efficacy Between Regimens in the Initial Treatment of Autoimmune Hepatitis
Elmer Original Article ress Comparing Efficacy Between Regimens in the Initial Treatment of Autoimmune Hepatitis Chijioke Enweluzo a, b, Fahad Aziz a, Amit Mori a Abstract Background: Autoimmune hepatitis
More informationDATA SHEET DANTRIUM Capsules
DATA SHEET DANTRIUM Capsules (dantrolene sodium) DESCRIPTION Dantrolene sodium is1-{[5-(p-nitrophenyl) furfurylidene]amino} hydantoin sodium hydrate. It is an orange powder, slightly soluble in water,
More informationType of intervention Treatment. Economic study type Cost-effectiveness analysis.
Costs and consequences of botulinum toxin type A use: management of children with cerebral palsy in Germany Ruiz F J, Guest J F, Lehmann A, Davie A M, Guttler K, Schluter O, Dreiss G Record Status This
More informationHepatitis C Virus Infection in Diabetes Mellitus Patients
599 Hepatitis C Virus Infection in Diabetes Mellitus Patients Han Ni*, Soe Moe, Aung Htet 1 Assistant Professor, Department of Medicine, Melaka Manipal Medical College, Malaysia 2 Associate Professor,
More informationKorean Journal of Medicine
Vol. 57, Suppl. II October, 1999 ISSN 1226-329X Korean Journal of Medicine 51th Meeting The Korean Association of Internal Medicine Fall Meeting Oral Presentation and Poster Section October 22-23, 1999
More informationDisclosures. How do statins work? Statin Pharmacokinetics 9/12/2013 THERAPEUTIC INTERVENTIONS FOR STATIN INTOLERANT PATIENTS
Disclosures Speakers Bureau- LipoScience Inc. THERAPEUTIC INTERVENTIONS FOR STATIN INTOLERANT PATIENTS Casey Elkins, DNP, NP-C, CLS How do statins work? Bays H, Stein EA. Expert Opin Pharmacother. 2003;4(11):1901-1938.
More informationAssessing the patient with a new diagnosis of Hepatitis C LAUREN MYERS MMSC, PA-C OREGON HEALTH & SCIENCE UNIVERSITY
Assessing the patient with a new diagnosis of Hepatitis C LAUREN MYERS MMSC, PA-C OREGON HEALTH & SCIENCE UNIVERSITY Disclosures Nothing to Disclose Assessing the patient with a new diagnosis of Hepatitis
More informationInvestigating and Referring Incidental Findings of Abnormal Liver Tests
Investigating and Referring Incidental Findings of Abnormal Liver Tests Note on Referral Guidelines: these revised guidelines are presented as a tool to aid appropriate referral and management of common
More informationSERUM CYSTATIN C CONCENTRATION IS A POWERFUL PROGNOSTIC INDICATOR IN PATIENTS WITH CIRRHOTIC ASCITES
SERUM CYSTATIN C CONCENTRATION IS A POWERFUL PROGNOSTIC INDICATOR IN PATIENTS WITH CIRRHOTIC ASCITES YEON SEOK SEO, 1 SOO YOUNG PARK, 2 MOON YOUNG KIM, 3 SANG GYUNE KIM, 4 JUN YONG PARK, 5 HYUNG JOON YIM,
More informationUnderstanding Blood Tests
PATIENT EDUCATION patienteducation.osumc.edu Your heart pumps the blood in your body through a system of blood vessels. Blood delivers oxygen and nutrients to all parts of the body. It also carries away
More informationTB Case Management Hepatitis
TB Case Management Hepatitis Chris Keh, MD TB Controller, TB Prevention and Control Program, San Francisco Department of Public Health Assistant Clinical Professor, Division of Infectious Diseases, University
More informationOccupational Hepatic Disorders in Korea
REVIEW Occupation & Environmental Medicine DOI: 10.3346/jkms.2010.25.S.S36 J Korean Med Sci 2010; 25: S36-40 Occupational Hepatic Disorders in Korea Hyoung Ryoul Kim 1, and Tae Woo Kim 2 Department of
More informationSupplementary Online Content
Supplementary Online Content Powles T, O Donnell PH, Massard C, et al. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 openlabel
More informationHIGHLIGHTS OF PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PIOGLITAZONE TABLETS, USP safely and effectively. See full prescribing information for PIOGLITAZONE
More informationSupplementary materials
Supplementary materials Table S Adverse events identified by participants diary logs and blood hematologic and biochemical tests (n=2) group (n=) Placebo group (n=) P value for chi-squared test Asthma
More informationTerbinafine hepatotoxicity. A case report and review of literature
Annals of Hepatology 2003; 2(1): January-March: 47-51 Case Report Annals of Hepatology Terbinafine hepatotoxicity. A case report and review of literature Alfonso Javier Zapata Garrido, 1 Alberto Casillas
More informationPediatric PSC A children s tale
Pediatric PSC A children s tale September 8 th PSC Partners seeking a cure Tamir Miloh Assistant Professor Pediatric Hepatology Mount Sinai Hospital, NY Incidence Primary Sclerosing Cholangitis (PSC) ;
More informationKynamro. Kynamro (mipomersen) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.02 Subject: Kynamro Page: 1 of 5 Last Review Date: December 2, 2016 Kynamro Description Kynamro (mipomersen)
More informationAutoimmune Hepatobiliary Diseases PROF. DR. SABEHA ALBAYATI CABM,FRCP
Autoimmune Hepatobiliary Diseases PROF. DR. SABEHA ALBAYATI CABM,FRCP Autoimmune hepatobiliary diseases The liver is an important target for immunemediated injury. Three disease phenotypes are recognized:
More informationNivolumab and Ipilimumab
Nivolumab and Ipilimumab Indication Advanced (unresectable or metastatic) melanoma. (NICE TA400) ICD-10 codes Codes prefixed with C43 Regimen details Cycles 1-4 Nivolumab and Ipilimumab every 3 weeks Day
More informationDosage and Administration
SIRTURO product information for healthcare providers 2 WARNINGS: An increased risk of death was seen in the SIRTURO (bedaquiline) treatment group (9/79, 11.4%) compared to the placebo treatment group (2/81,
More informationClodronate BE/H/PSUR/001/001 October 2011 Agreed CSP
Clodronate BE/H/PSUR/001/001 October 2011 Agreed CSP 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Intravenous use Treatment of hypercalcemia due to malignancy. Oral use Treatment of hypercalcemia
More informationTHE CLINICAL USE OF BOTULINUM TOXIN IN THE TREATMENT OF MOVEMENT DISORDERS, SPASTICITY, AND SOFT TISSUE PAIN
THE CLINICAL USE OF BOTULINUM TOXIN IN THE TREATMENT OF MOVEMENT DISORDERS, SPASTICITY, AND SOFT TISSUE PAIN Spasmodic torticollis (cervical dystonia), blepharospasm, and writer s cramp are specific types
More informationNew Evidence reports on presentations given at EULAR Safety and Efficacy of Tocilizumab as Monotherapy and in Combination with Methotrexate
New Evidence reports on presentations given at EULAR 2009 Safety and Efficacy of Tocilizumab as Monotherapy and in Combination with Methotrexate Report on EULAR 2009 presentations Tocilizumab inhibits
More informationBCCA Protocol Summary for Treatment of Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia Using PONAtinib
BCCA Protocol Summary for Treatment of Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia Using PONAtinib Protocol Code Tumour Group Contact Physician ULKCMLP Leukemia Dr. Donna Forrest ELIGIBILITY:
More informationCaution: Reactivation of Hepatitis B during Hepatitis C Treatment with Direct-Acting Antiviral Therapy
Caution: Reactivation of Hepatitis B during Hepatitis C Treatment with Direct-Acting Antiviral Therapy Anjana A. Pillai, Emory University Frank A Anania, Emory University Brian L. Pearlman, Emory University
More informationNCCP Chemotherapy Protocol. Ponatinib Therapy
INDICATIONS FOR USE: INDICATION Treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant
More informationMUSCULOSKELETAL AND NEUROLOGICAL DISORDERS
MUSCULOSKELETAL AND NEUROLOGICAL DISORDERS There are a wide variety of Neurologic and Musculoskeletal disorders which can impact driving safety. Impairment may be the result of altered muscular, skeletal,
More informationIpilimumab Monotherapy
INDICATIONS FOR USE: Ipilimumab INDICATION ICD10 Regimen Code *Reimbursement Indicator Treatment of advanced (unresectable or metastatic) melanoma in adults C43 00105a ODMS *If a reimbursement indicator
More informationRole of Intrathecal Baclofen. Mr. Chirag Patel Consultant Paediatric Neurosurgeon Children s Hospital for Wales, Cardiff.
Role of Intrathecal Baclofen Mr. Chirag Patel Consultant Paediatric Neurosurgeon Children s Hospital for Wales, Cardiff. History of Intrathecal Baclofen therapy 1978: First used in guinea pigs by Wilson.
More informationO CH. N NNa. x H 2 O. Dantrium is supplied in capsules of 25 mg, 50 mg, and 100 mg.
Dantrium (dantrolene sodium) capsules Dantrium (dantrolene sodium) has a potential for hepatotoxicity, and should not be used in conditions other than those recommended. Symptomatic hepatitis (fatal and
More informationLapatinib and Capecitabine Therapy
Lapatinib and Capecitabine Therapy This protocol should be read in conjunction with NCCP protocol 00216 Capecitabine Monotherapy. INDICATIONS FOR USE: INDICATION Treatment of adult patients with breast
More informationOverview. Spasticity. Spasticity. Oral Medications. Spasticity 3/10/2012. Medication Management of Spasticity in the Traumatic Brain Injured Patient
Medication Management of in the Traumatic Brain Injured Patient 6 th Annual Northern Kentucky TBI Conference March 23, 2012 www.bridgesnky.org Chad Walters, D.O. Medical Director Radical Rehab Solutions
More informationNCCP Chemotherapy Regimen. Alectinib Monotherapy
INDICATIONS FOR USE: Alectinib INDICATION ICD10 Regimen Code *Reimbursement Indicator Treatment of adult patients with anaplastic lymphoma kinase (ALK)- positive advanced non-small cell lung cancer (NSCLC)
More informationTHAI J GASTROENTEROL 2014 Vol. 15 No May - Aug. 2014
Case Report Poovorawan K, et al. 105 Fatal Acute-on-Chronic Liver Failure from Amiodarone Toxicity Poovorawan K 1,2 Wisedopas N 3 Treeprasertsuk S 1 Komolmit P 1 ABSTRACT Background: Drug induced liver
More informationLiver Function Tests. Dr. Abdulhussien Aljebory Babylon university College of Pharmacy
Liver Function Tests Dr. Abdulhussien Aljebory Babylon university College of Pharmacy FUNCTIONS OF LIVER Metabolic function Excretory function Synthetic fuction Detoxification function Storage function
More informationLeonard B. Seeff, M.D. Consultant Einstein Healthcare Network. Click to view Biosketch and Presentation Abstract or page down to review presentation
Leonard B. Seeff, M.D. Consultant Einstein Healthcare Network Click to view Biosketch and Presentation Abstract or page down to review presentation ALT as a Biomarker for Drug-Induced Liver Injury Leonard
More informationNovedades en el tratamiento de la hepatitis B: noticias desde la EASL. Maria Buti Hospital Universitario Valle Hebrón Barcelona
Novedades en el tratamiento de la hepatitis B: noticias desde la EASL Maria Buti Hospital Universitario Valle Hebrón Barcelona Milestones in CHB treatment Conventional IFN 1991 Lamivudine (LAM) 1998 Adefovir
More informationNeuromuscular Junction
Muscle Relaxants Neuromuscular Junction Cholinergic antagonists Neuromuscular-blocking agents (mostly nicotinic antagonists): interfere with transmission of efferent impulses to skeletal muscles. These
More informationTECFIDERA (dimethyl fumarate) oral capsule
TECFIDERA (dimethyl fumarate) oral capsule Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationSojan George Kunnathuparambil, Kattoor Ramakrishnan Vinayakumar, Mahesh R. Varma, Rony Thomas, Premaletha Narayanan, Srijaya Sreesh
Original article Annals of Gastroenterology (2013) 26, 1-5 Bilirubin, aspartate aminotransferase and platelet count score: a novel score for differentiating patients with chronic hepatitis B with acute
More informationDrug-induced hepatotoxicity is a well-recognized adverse. Incidence of Statin Hepatotoxicity in Patients With Hepatitis C
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4:902 907 Incidence of Statin Hepatotoxicity in Patients With Hepatitis C SHIRIN KHORASHADI,* NOELLE K. HASSON,* and RAMSEY C. CHEUNG, *Pharmacy Service, and
More informationDoes Viral Cure Prevent HCC Development
Does Viral Cure Prevent HCC Development Prof. Henry LY Chan Head, Division of Gastroenterology and Hepatology Director, Institute of Digestive Disease Director, Center for Liver Health Assistant Dean,
More informationDepartment of Rehabilitation Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Korea
Original Article Ann Rehabil Med 2015;39(4):624-629 pissn: 2234-0645 eissn: 2234-0653 http://dx.doi.org/10.5535/arm.2015.39.4.624 Annals of Rehabilitation Medicine Gross Motor Function Outcome After Intensive
More informationCarboplatin and Fluorouracil
Carboplatin and Fluorouracil Indication Palliative chemotherapy for recurrent or metastatic head and neck squamous cell cancer for patients where cisplatin and / or cetuximab are not appropriate. Performance
More informationYONDELIS (trabectedin) DOSING & ADMINISTRATION GUIDE
YONDELIS (trabectedin) DOSING & ADMINISTRATION GUIDE INDICATION YONDELIS (trabectedin) is indicated for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received
More informationPazopanib (Continuous vs Drug-free Interval Strategy) STAR Trial
Pazopanib (Continuous vs Drug-free Interval Strategy) STAR Trial A Randomised Multi-Stage Phase II/III Trial of Standard first-line therapy (sunitinib or pazopanib) Comparing Temporary Cessation with Allowing
More informationIpilimumab (skin) Indication Advanced (unresectable or metastatic) melanoma in patients who have received prior therapy.
Ipilimumab (skin) Indication Advanced (unresectable or metastatic) melanoma in patients who have received prior therapy. (NICE TA268) ICD-10 codes Codes prefixed with C43 Regimen details Day Drug Dose
More informationDoes hydrocodone raise ast and alt levels
Does hydrocodone raise ast and alt levels The Borg System is 100 % Does hydrocodone raise ast and alt levels Jul 3, 2012. In order to accurately assess and develop the proper treatment plan for the patient
More informationShould There Be a Standard of Care (SOC) for Drug-Induced Liver Injury (DILI)? Leonard B Seeff, MD
Should There Be a Standard of Care (SOC) for Drug-Induced Liver Injury (DILI)? Leonard B Seeff, MD Drug-Induced Liver Injury: Are We Ready to Look? March 23-24,2011 AASLD, FDA/CDER, PhRMA A Common Statement
More informationDocetaxel + Nintedanib
Docetaxel + Nintedanib Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Indication Second
More informationATEZOLIZUMAB (TECENTRIQ ) in urothelial carcinoma
DRUG ADMINISTRATION SCHEDULE Day Drug Daily Dose Route Diluent Rate Day 1 Atezolizumab 1200 mg IV Infusion 250mL 0.9% Sodium Chloride Over 60 minutes* *The initial dose of atezolizumab must be administered
More informationIntron A (interferon alfa-2b) with ribavirin, (Moderiba, Rebetol, Ribasphere, RibaTab, ribavirin tablets/capsules - all strengths)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.06 Subject: Intron A Ribavirin Page: 1 of 6 Last Review Date: March 18, 2016 Intron A Ribavirin Description
More informationMagnetic Resonance Cholangiopancreatography (MRCP) in a District General Hospital
Magnetic Resonance Cholangiopancreatography (MRCP) in a District General Hospital Poster No.: C-1790 Congress: ECR 2012 Type: Authors: Scientific Exhibit J. A. Maguire 1, H. Kasem 2, M. Akhtar 2, M. Strauss
More informationHBV Forum 2 April 18 th 2017 Hilton Amsterdam.
HBV Forum 2 April 18 th 2017 Hilton Amsterdam www.forumresearch.org Detection, Assessment and Management of DILI During Drug Development for HBV: The IQ DILI Initiative. Arie Regev, MD Global Patient Safety
More informationA study of effect of alcohol on liver function tests (LFT) in Garhwal hills, India
International Journal of Research in Medical Sciences Gogoi JB et al. Int J Res Med Sci. 2018 Jan;6(1):94-98 www.msjonline.org pissn 2320-6071 eissn 2320-6012 Original Research Article DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20175536
More informationELSPAR (asparaginase) For injection, intravenous or intramuscular Initial U.S. Approval: 1978
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Elspar safely and effectively. See full prescribing information for Elspar. ELSPAR (asparaginase)
More informationKynamro. Kynamro (mipomersen) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.02 Subject: Kynamro Page: 1 of 5 Last Review Date: September 15, 2017 Kynamro Description Kynamro
More information